Fluidigm (NASDAQ:FLDM) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

A number of other research analysts also recently commented on the stock. Piper Jaffray Companies reaffirmed a “hold” rating and set a $6.10 price objective on shares of Fluidigm in a research note on Thursday, February 8th. ValuEngine downgraded shares of Fluidigm from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.

Fluidigm (FLDM) opened at $7.19 on Tuesday. Fluidigm has a one year low of $2.52 and a one year high of $7.75. The company has a current ratio of 3.02, a quick ratio of 2.46 and a debt-to-equity ratio of 5.00. The company has a market cap of $264.35, a PE ratio of -3.78 and a beta of 3.24.

Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Fluidigm had a negative net margin of 59.38% and a negative return on equity of 116.02%. The company had revenue of $27.75 million for the quarter, compared to analyst estimates of $27.14 million. During the same period in the prior year, the company earned ($0.32) EPS. The company’s revenue was up 10.6% compared to the same quarter last year. sell-side analysts forecast that Fluidigm will post -0.7 earnings per share for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. bought 53,610 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average price of $5.73 per share, with a total value of $307,185.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders have purchased 482,624 shares of company stock valued at $2,917,895. Corporate insiders own 4.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Levin Capital Strategies L.P. increased its position in Fluidigm by 5.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 9,167,070 shares of the medical research company’s stock worth $53,994,000 after purchasing an additional 463,310 shares in the last quarter. Neuberger Berman Group LLC increased its position in Fluidigm by 181.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 5,213,481 shares of the medical research company’s stock worth $26,276,000 after purchasing an additional 3,362,100 shares in the last quarter. Russell Investments Group Ltd. increased its position in Fluidigm by 46.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,447,491 shares of the medical research company’s stock worth $17,370,000 after purchasing an additional 1,099,072 shares in the last quarter. BlackRock Inc. increased its position in Fluidigm by 18.3% during the 4th quarter. BlackRock Inc. now owns 2,184,882 shares of the medical research company’s stock worth $12,870,000 after purchasing an additional 337,639 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Fluidigm by 20.1% during the 4th quarter. Renaissance Technologies LLC now owns 805,300 shares of the medical research company’s stock worth $4,743,000 after purchasing an additional 134,700 shares in the last quarter. 94.79% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/15/fluidigm-fldm-upgraded-by-bidaskclub-to-strong-buy.html.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.